English-language podcasts

Podcasts

Biotech Hangout

An episode can be the start of a conversation. Explore recent releases, share your thoughts, and meet through a ThinkMatch Roundtable.

Ask friends about this

Episodes to discuss

Biotech Hangout

Episode 204 - November 20, 2026

60 min

On this week’s episode, Graig Suvannavejh, Tim Opler, BrianSkorney, Chris Garabedian, and Matt Gline opened with a look at the biotech market, with the XBI up roughly 17% to 18% year to date, though the group noted that AI-driven demand for capital and the possibility of an AI bubble are weighing on sentiment. The co-hosts then discussed expectations for 2027 as a significant M&A year, following conversations with pharma M&A leaders at the Jefferies Global Healthcare Conference. The group also covered the withdrawal of Heidi Overton’s FDA Commissioner nomination and what the uncertainty could mean for agency stability and volatility. Next, they discussed market rumors of a potential Sanofi acquisition of Insmed, including Brinsupri’s performance and raised guidance, and what a deal of that size could signal for the broader M&A landscape. The group also covered Lilly’s oncology deals with Stipple Bio and Calytrix, and the growing opacity of biobucks headlines and undisclosed upfront pay

Discuss this episode

Biotech Hangout

Episode 203 - November 13, 2026

62 min

On this week’s episode, Eric Schmidt, Yaron Werber, Paul Matteis, and Kate Haviland opened with a look at the biotech market, with the XBI up roughly 25% year to date, though it feels much worse to many buy-side clients. The group discussed the midterm elections, weighing a potential blue wave against a market pricing in two more rate hikes. They also previewed next week’s Senate vote on Dr. Heidi Overton’s nomination as FDA commissioner, with Paul sharing his conversation with former FDA Commissioner Scott Gottlieb at the Stifel Healthcare Conference, where Gottlieb expressed optimism about her confirmation and her grasp of the agency’s need to rehire and rebuild expertise. The co-hosts then discussed the longer-term future of MFN deals, including sunset provisions and the question of whether the policy returns. The conversation turned to drug launches, covering how companies set expectations through pre-launch conversations with clinicians, office staff, and patients, and whether exp

Discuss this episode

Biotech Hangout

Episode 202 - November 6, 2026

61 min

On this week’s episode, Brian Skorney, Paul Matteis, Yaron Werber, and Adam Feuerstein opened with a look at what the midterm results could mean for biotech, covering the macro backdrop, the FDA, and drug pricing. The conversation then turned to Vertex’s povetacicept ahead of a potential IgAN approval at the end of November, and the competitive landscape as Vertex enters a market with two formidable competitors. In earnings news, the group discussed Revolution Medicines’ strong Q3 launch sales for Rasonque, which doubled market predictions, and the safety questions and possible label changes facing Neurocrine’s Vykat. The group also covered the race for the first FDA approval of a psilocybin depression treatment, with Compass nearing NDA completion and a reported filing from the Usona Institute, as well as Novartis’ update on tumor cases in Zolgensma-treated patients. The episode closed with the Phase 3 miss for Novartis and Ionis’ pelacarsen despite significant Lp(a) reduction, and wh

Discuss this episode